US2005129737A1PendingUtilityA1

Devices and methods for pain management

Priority: Mar 18, 1999Filed: Jan 26, 2005Published: Jun 16, 2005
Est. expiryMar 18, 2019(expired)· nominal 20-yr term from priority
A61K 47/26A61K 31/4468A61K 9/0019A61K 47/14A61K 9/0014A61K 31/4535A61K 9/0024A61K 9/0004A61M 37/0069A61P 25/00A61K 47/10A61P 25/04
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a matrix within the controlled drug delivery device). The drug formulation comprises an amount of drug sufficient for treatment and is stable at body temperatures (i.e. no unacceptable degradation) for the entire pre-selected treatment period. The drug delivery devices store the drug formulation safely (e.g., without dose dumping), provide sufficient protection from bodily processes to prevent unacceptable degradation of the formulation, and release the drug formulation in a controlled fashion at a therapeutically effective rate to treat pain. In use, the drug delivery device is implanted in the subject's body at an implantation site, and the drug formulation is released from the drug delivery device to a delivery site. The delivery site may be the same as, near, or distant from the implantation site. Once released at the delivery site, the drug formulation enters the systemic circulation and is transported to the site of action in the body to modulate the pain response (e.g., the brain or other pain sensory location).

Claims

exact text as granted — not AI-modified
1 - 47 . (canceled)  
     
     
         48 . A method of inducing analgesia in a subject, the method comprising: 
 administration of sufentanil to the subject at a therapeutically effective rate to provide substantially continuous delivery of sufentanil at about 1 μg/hr over a period of at least 24 hours, wherein said administering induces analgesia in the subject.    
     
     
         49 . The method of  claim 48 , wherein said period is at least 3 days.  
     
     
         50 . The method of  claim 48 , wherein said period is at least 5 days.  
     
     
         51 . The method of  claim 48 , wherein said period is at least 10 days.  
     
     
         52 . The method of  claim 48 , wherein said period is at least 30 days.  
     
     
         53 . The method of  claim 48 , wherein said period is at least 90 days.  
     
     
         54 . The method of  claim 48 , wherein said period is at least 1 month.  
     
     
         55 . The method of  claim 48 , wherein said period is at least 6 months.  
     
     
         56 . The method of  claim 48 , wherein said period is at least 12 months.  
     
     
         57 . A method of inducing analgesia in a subject, the method comprising: 
 administration of sufentanil to the subject at a therapeutically effective rate to provide substantially continuous delivery of sufentanil at about 2.5 μg/hr over a period of at least 24 hours, wherein said administering induces analgesia in the subject.    
     
     
         58 . The method of  claim 57 , wherein said period is at least 3 days.  
     
     
         59 . The method of  claim 57 , wherein said period is at least 5 days.  
     
     
         60 . The method of  claim 57 , wherein said period is at least 10 days.  
     
     
         61 . The method of  claim 57 , wherein said period is at least 30 days.  
     
     
         62 . The method of  claim 57 , wherein said period is at least 90 days.  
     
     
         63 . The method of  claim 57 , wherein said period is at least 1 month.  
     
     
         64 . A method of inducing analgesia in a subject, the method comprising: 
 administration of sufentanil to the subject at a therapeutically effective rate to provide substantially continuous delivery of sufentanil at about 3 μg/hr over a period of at least 24 hours, wherein said administering induces analgesia in the subject.    
     
     
         65 . The method of  claim 64 , wherein said period is at least 3 days.  
     
     
         66 . The method of  claim 64 , wherein said period is at least 5 days.  
     
     
         67 . The method of  claim 64 , wherein said period is at least 10 days.  
     
     
         68 . The method of  claim 64 , wherein said period is at least 30 days.  
     
     
         69 . The method of  claim 64 , wherein said period is at least 90 days.  
     
     
         70 . The method of  claim 64 , wherein said period is at least 1 month.

Join the waitlist — get patent alerts

Track US2005129737A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.